• Product nameAnti-IL6 antibody [B-E8]
    See all IL6 primary antibodies
  • Description
    Mouse monoclonal [B-E8] to IL6
  • Specificityab11449 reacts with natural and recombinant human IL6. We have data to indicate that this antibody may not cross react with Mouse. However, this has not been conclusively tested and expression levels may vary in certain cell lines/tissues.
  • Tested applicationsSuitable for: IHC-Fr, ELISA, Neutralisingmore details
    Unsuitable for: IHC-P
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Human recombinant IL6.

  • General notesStorage in frost free freezers is not recommended. Should this product contain a precipitate we recommend microcentrifugation before use.



Our Abpromise guarantee covers the use of ab11449 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr Use at an assay dependent concentration.
ELISA Use at an assay dependent concentration.
Neutralising Use at an assay dependent concentration. 20pg neutralizes activity of 1U of IL6. For this application removal of azide is recommended.
  • Application notesIs unsuitable for IHC-P.
  • Target

    • FunctionCytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
    • Involvement in diseaseGenetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
      Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
    • Sequence similaritiesBelongs to the IL-6 superfamily.
    • Post-translational
      N- and O-glycosylated.
    • Cellular localizationSecreted.
    • Information by UniProt
    • Database links
    • Alternative names
      • Interleukin BSF 2 antibody
      • B cell differentiation factor antibody
      • B cell stimulatory factor 2 antibody
      • B-cell stimulatory factor 2 antibody
      • BSF 2 antibody
      • BSF-2 antibody
      • BSF2 antibody
      • CDF antibody
      • CTL differentiation factor antibody
      • Hepatocyte stimulatory factor antibody
      • HGF antibody
      • HSF antibody
      • Hybridoma growth factor antibody
      • Hybridoma growth factor Interferon beta-2 antibody
      • IFN-beta-2 antibody
      • IFNB2 antibody
      • IL 6 antibody
      • IL-6 antibody
      • IL6 antibody
      • IL6_HUMAN antibody
      • Interferon beta 2 antibody
      • Interferon beta-2 antibody
      • Interleukin 6 antibody
      • Interleukin 6 (interferon beta 2) antibody
      • Interleukin BSF 2 antibody
      • Interleukin-6 antibody
      see all

    References for Anti-IL6 antibody [B-E8] (ab11449)

    This product has been referenced in:
    • Cejková J  et al. Favorable effects of trehalose on the development of UVB-mediated antioxidant/pro-oxidant imbalance in the corneal epithelium, proinflammatory cytokine and matrix metalloproteinase induction, and heat shock protein 70 expression. Graefes Arch Clin Exp Ophthalmol 249:1185-94 (2011). IHC-Fr ; Rabbit . Read more (PubMed: 21494875) »
    • Zenkel M  et al. Proinflammatory cytokines are involved in the initiation of the abnormal matrix process in pseudoexfoliation syndrome/glaucoma. Am J Pathol 176:2868-79 (2010). IHC-Fr ; Human . Read more (PubMed: 20395431) »

    See all 4 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab11449.
    Please use the links above to contact us or submit feedback about this product.